✦ LIBER ✦

Alveolar hemorrhage due to erlotinib in non-small-cell lung cancer resistant to gefitinib

✍ Scribed by Yano Shuichi

Book ID: 113878259
Publisher: Elsevier
Year: 2010
Tongue: English
Weight: 262 KB
Volume: 3
Category: Article
ISSN: 1755-0017
DOI: 10.1016/j.rmedc.2009.02.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib response of EGFR-mutant gefiti

Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer

✍ Chang, John Wen-Cheng; Chou, Chun-Liang; Huang, Shiu-Feng; Wang, Hung-Ming; Hsie 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 414 KB

Response to gefitinib and erlotinib in N

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

✍ Ivette F Emery; Chiara Battelli; Paul L Auclair; Kathleen Carrier; Daniel M Haye 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 574 KB

Erlotinib in advanced non-small-cell lun

Erlotinib in advanced non-small-cell lung cancer after gefitinib failure

✍ Zheng-Tao Zhou; Xin-Hua Xu; Qing Wei; Ming-qian Lu; Jie Wang; Cai-Hong Wen 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 262 KB

EGFR Mutation and Resistance of Non–Smal

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

✍ Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jänne, Pasi A.; Kocher, Ol 📂 Article 📅 2005 🏛 Massachusetts Medical Society 🌐 English ⚖ 256 KB

Erlotinib as salvage treatment after fai

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

✍ Matthew K. Wong; Alvis I. Lo; Bing Lam; W. K. Lam; Mary S. Ip; James C. Ho 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 197 KB

Establishment of a human non-small cell

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib

✍ Fumiaki Koizumi; Tatsu Shimoyama; Fumiko Taguchi; Nagahiro Saijo; Kazuto Nishio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 672 KB

## Abstract The epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor gefitinib (Iressa®, ZD1839) has shown promising activity preclinically and clinically. Because comparative investigations of drug‐resistant sublines with their parental cells are useful approaches to identifying the m